B2BROKER
9.9.2020 11:02:14 CEST | Business Wire | Press release
B2B Payment Solutions Ltd , part of the B2Broker Group of companies, is pleased to announce that the United Kingdom’s Financial Conduct Authority (FCA) has granted the company an Electronic Money Institution License (AEMI). The licence permits companies to engage in e-money related and payment services in the UK and European Economic Area (EEA).
As a regulated AEMI e-money provider, B2B Payment Solutions Ltd will now be able to act as a payment intermediary. The company’s primary focus is to offer payment services to regulated Forex brokers and licensed liquidity providers as well as corporate IT businesses and e-commerce companies, and create a bespoke ecosystem where brokers will be able to deposit and withdraw funds to and from margin accounts and their end-users across Europe and the UK.
The company will therefore offer digital banking services that are ideally geared up for the regulated brokerage industry. According to company estimations, there are over 1,000 regulated brokers and liquidity providers with hundreds of thousands of end users, all of whom will be able to deposit and withdraw in just seconds. In this respect, B2B Payment Solutions Ltd will offer sub IBANs, SEPA transfers and Faster Payments.
Future plans include the addition of further services including SWIFT transfers, card processing and electronic money wallets. The company also intends to start offering the same services to other types of regulated financial institutions who possess PI, API, EMI and AEMI licenses.
Ievgen Iugrinov, the company's Product Manager commented, “Our goal is to enable the B2Broker ecosystem to access payment accounts and attract new clients to the financial industry. We are delighted to be able to offer the latest genre of e-payment services as an AEMI which places us in the same league as leading industry players who also conduct their UK and European operations under the same licence.”
Securing an AEMI licence is a key part of the company's strategy to expand its products globally and extend its services and offer better and more competitive products to its customers across the UK and Europe.
Established in 2020, B2B Payment Solutions Ltd (ref no: 901100) is a financial technology company headquartered in London, UK offering a range of digital banking and payment services.
These include worldwide money transfers, issuing e-wallets and prepaid cards, setting up direct debits, processing standing orders, BACS/CHAPS payments and mobile payment transactions. All payments are easy and secure, and using algorithms which trigger fraud, money laundering and other illicit activities.
Evgeniya Mykulyak, Co-Founder at B2B Payment Solutions Ltd added, “I believe we will offer a groundbreaking service to all users who need instant access to a range of e-payment services. We will be providing a range of services where our customers can be assured that their transactions will not only be fast, but safe and secure. With deep industry knowledge in the payments industry, our company has big plans for the future which will firmly place us in a prime position in the Fintech industry.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20200909005413/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
